FDA Inspection

SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)March 15, 2024

FDA Inspection 1233707 - SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals) - March 15, 2024

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

This FDA Inspection record concerns SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals), with an inspection on March 15, 2024, issued by the Center for Biologics Evaluation and Research, covering biologics.

Company: SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)
Inspection Date: March 15, 2024
Product Type: Biologics
Office: Center for Biologics Evaluation and Research

Open in Dashboard

ID · 064ffa75-823f-4b4a-ac70-4da31c81faa0

Violation Codes1

21 CFR 211.160(b)

Full citation text and observation details available on the Dashboard.